Autoimmune Lymphoproliferative Syndrome Type 4 (ALPS-4)

Autoimmune lymphoproliferative syndrome type 4 is a rare immune system problem. In this condition, white blood cells do not switch off and die when they should. As a result, too many lymphocytes build up in the body. This causes big lymph nodes and a large spleen or liver, and it can cause autoimmune attacks on blood cells (anemia, low platelets, or low neutrophils). What used to be called “ALPS type 4” is now better named RAS-associated autoimmune leukoproliferative disease (RALD). It is usually caused by somatic (post-birth) gain-of-function mutations in the RAS pathway, most often NRAS (and sometimes KRAS). These mutations make survival signals inside lymphocytes too strong, so cells resist normal Fas-mediated “programmed death” and keep accumulating. Orpha+3ASH Publications+3PNAS+3

People with RALD/ALPS-4 often have long-lasting swollen lymph nodes and big spleen, high antibodies in the blood (hypergammaglobulinemia), and repeated autoimmune “cytopenias” such as autoimmune hemolytic anemia and immune thrombocytopenia. Many were first evaluated as having classical ALPS because the symptoms look similar, but genetic testing and laboratory features show the RAS pathway cause. PMC+2MedlinePlus+2

Autoimmune Lymphoproliferative Syndrome type 4 (ALPS-4) is a rare immune system disorder in which certain white blood cells do not die when they should. Because these cells survive too long, the immune system becomes too “crowded” and misdirected. Children or adults develop long-lasting swollen lymph nodes and an enlarged spleen, and many people also develop autoimmune problems such as anemia or low platelets. ALPS-4 is driven by activating (gain-of-function) mutations in the RAS pathway genes, most often NRAS or KRAS. It was once grouped as “type 4 ALPS,” but today many experts call it RAS-associated autoimmune leukoproliferative disorder (RALD) because it behaves a bit differently from classic ALPS caused by defects in the FAS “death receptor” pathway. NCBI+2PMC+2

In classic ALPS, the problem is failure of the FAS-mediated apoptosis pathway; in ALPS-4/RALD the defect is in a secondary apoptosis control pathway downstream of RAS–MAPK. The end result is similar—too many long-lived lymphocytes and a tendency toward autoimmunity—but lab patterns and genetics are distinct, which matters for diagnosis and counseling. NCBI+1

Other names

Doctors and laboratories may use different labels for the same condition. You may see:
RALD (RAS-associated autoimmune leukoproliferative disorder); ALPS-IV or ALPS type 4 (older term); NRAS/KRAS-associated autoimmune lymphoproliferation. These all point to the same biology—somatic (sometimes mosaic) activating mutations in NRAS or KRAS that cause chronic lymphoproliferation and autoimmunity. NCBI+2BioMed Central+2

Types

Because the disease is rare, there is no single universal “type list,” but clinicians commonly sort cases into practical subgroups:

1. By gene: NRAS-positive vs KRAS-positive. Both cause a very similar picture; both are typically somatic (found in blood cells). NCBI

2. By mutation hotspot: codon 12, 13, or 61 variants (for example NRAS p.G13D or KRAS p.G12D), which are classic activating sites in RAS disorders. This helps labs interpret genetic results. PMC

3. By cell distribution: mutations confined to hematopoietic cells (most common) vs broader mosaicism across tissues. This can influence how widely the variant is detected and may relate to cancer risk. NCBI

4. By clinical onset: childhood-onset vs adult-onset disease; both are reported, with median onset around early childhood in case series. PubMed

5. By laboratory phenotype: those with normal vs elevated double-negative T cells (DNTs). Elevated αβ-DNTs are typical for classic ALPS but may be normal or only mildly raised in RALD/ALPS-4. BioMed Central

Causes

ALPS-4 has a core cause (activating RAS mutations) and modifiers that shape how it looks in real life. Each item below is a short, plain-language paragraph about a known or plausible driver with evidence where available.

1. Somatic NRAS gain-of-function mutation. A change in NRAS turns on growth signals inside white blood cells, so they live longer and pile up in lymph nodes and spleen. This is the single most common cause of RALD/ALPS-4. NCBI

2. Somatic KRAS gain-of-function mutation. The same “stuck-on” signal in KRAS produces the same pattern of swollen nodes, big spleen, and autoimmune low blood counts. PMC

3. Mutation at RAS codon 12. Changes at this hotspot make the protein hard to switch off, driving constant survival signals. PMC

4. Mutation at RAS codon 13. Similar to codon 12, codon-13 variants keep RAS active and block normal cell death. PMC

5. Mutation at RAS codon 61. Another classic activating site that stabilizes the “on” state, sustaining lymphocyte survival. PMC

6. Hematopoietic-restricted mosaicism. If only blood-forming cells carry the mutation, the immune system is mostly affected, explaining the lab pattern and clinical features. NCBI

7. High RAS–MAPK signaling (pERK) in lymphocytes. Overactive downstream signaling supports cell survival and autoimmunity; labs sometimes demonstrate this biochemically. PMC

8. Secondary apoptosis pathway failure. Even with normal FAS testing, the “backup” pathways that prune immune cells are impaired by RAS activation. NCBI

9. Autoantibody formation. Overactive or misregulated B/T cells make antibodies that attack blood cells, causing autoimmune cytopenias (anemia, thrombocytopenia, neutropenia). NCBI

10. Hypergammaglobulinemia. Elevated antibodies reflect chronic activation and help flag an autoimmune process in the lab workup. htct.com.br

11. Expanded long-lived lymphocytes. Flow cytometry shows expanded populations that do not undergo normal cell death, a hallmark of lymphoproliferation. NCBI

12. Monocytosis. High monocyte counts are common and can help separate RALD/ALPS-4 from classic ALPS in the clinic. BioMed Central

13. Infections as triggers. Common infections may “unmask” the condition by stimulating the immune system, revealing swollen nodes and cytopenias that do not settle. Primary Immune

14. Overlap with myeloid disease biology. Because the same RAS mutations appear in some myeloid cancers, vigilance for myeloid changes is warranted in a minority of cases. ASH Publications

15. Somatic mutation burden / variant allele fraction. The proportion of cells carrying the mutation can influence how severe or persistent the features are. NCBI

16. Immune system age. Younger immune systems may show bigger lymph nodes and spleens; adults may have a subtler course at first recognition. PubMed

17. Co-existing immune gene variants (ALPS-like). Some patients carry changes in other immune genes that modify the look of the disease, which broad NGS panels can detect. Mayo Clinic Laboratories

18. Environmental immune stimulation. Ongoing antigen exposure (e.g., chronic viral infections) can amplify the underlying survival signal and autoimmunity. Primary Immune

19. Cytokine milieu. Chronic immune activation shifts cytokines toward survival and autoantibody production, feeding the loop of lymphoproliferation. Europe PMC

20. Diagnostic delay. When the diagnosis is delayed, repeated flares and treatments can “shape” the disease course, which is a practical, real-world modifier seen in case series. BioMed Central

 Common symptoms and signs

1. Painless, long-lasting swollen lymph nodes. The most visible sign—non-tender nodes in the neck, armpits, or groin that persist for months. PMC

2. Enlarged spleen (splenomegaly). Often noticed as a feeling of fullness on the left side or by a doctor on exam; it reflects cell buildup. NCBI

3. Enlarged liver (hepatomegaly). Less common than splenomegaly but part of the same process. NCBI

4. Easy bruising or bleeding. Due to autoimmune low platelets (ITP). NCBI

5. Fatigue and pallor. Often from autoimmune hemolytic anemia. NCBI

6. Frequent or prolonged fevers. Inflammation or intercurrent infections may cause recurrent fevers. PMC

7. Recurrent infections (some patients). Not all patients, but some have repeated respiratory or skin infections. NCBI

8. Low neutrophil counts. Autoimmune neutropenia can lead to mouth ulcers or infections. NCBI

9. Fullness or discomfort in the abdomen. Usually from a large spleen. PMC

10. Unintended weight loss or poor weight gain. In more active disease phases. PMC

11. Rashes or hives. Autoimmune activity can involve the skin in some patients. NCBI

12. Night sweats. Sometimes reported during flares of immune activation. PMC

13. Bone pain or aches. Less common, but may occur with marrow stress during cytopenia and recovery cycles. PMC

14. Mouth ulcers. Can be linked to neutropenia or immune activation. NCBI

15. Anxiety about cancer risk. A small subset progress toward myeloid neoplasms (e.g., JMML/AML), so doctors monitor closely; most do not develop cancer. PubMed

Diagnostic tests

How doctors think about testing: In ALPS-4/RALD the key is to prove chronic, non-malignant lymphoproliferation, document autoimmune cytopenias, exclude classic FAS-pathway ALPS, and find an activating NRAS or KRAS mutation—ideally restricted to blood cells. Genetic proof plus the clinical picture confirm the diagnosis. NCBI

A) Physical examination

1. Comprehensive lymph node exam. The doctor checks size, number, and areas involved; persistent, non-tender nodes support lymphoproliferation. PMC

2. Spleen and liver palpation. Feeling the abdomen for enlarged spleen/liver is routine and helps track disease over time. NCBI

3. Skin and mucosa check. Looks for bruising, petechiae, rashes, mouth ulcers—clues to autoimmune cytopenias or infection risk. NCBI

4. Vital signs and growth measures. Fever curves, weight, and height trends reveal inflammatory activity and chronic disease impact. PMC

B) Manual clinic tests and procedures

5. Bedside spleen size tracking. Tape-measure or ultrasound-guided marking across visits gives an objective trend of splenic enlargement. PMC

6. Monospot/rapid infection screens when nodes flare. Quick tests help rule out common reversible causes of lymph node swelling so persistent cases are recognized. Primary Immune

7. Direct antiglobulin test at bedside lab (Coombs). Often run urgently when anemia is suspected; a positive result supports autoimmune hemolysis. NCBI

8. Clinical response tests (e.g., steroid challenge) for cytopenias. Short trials can show autoimmunity when counts promptly rise, guiding urgent care while deeper testing proceeds. NCBI

C) Laboratory and pathology

9. Complete blood count with differential. Looks for anemia, thrombocytopenia, neutropenia, and particularly monocytosis, which is common in RALD/ALPS-4. BioMed Central

10. Reticulocyte count and hemolysis labs. LDH, bilirubin, haptoglobin help confirm autoimmune hemolysis. NCBI

11. Peripheral smear. Reviews cell shapes and flags atypical cells without the malignant patterns seen in leukemia/lymphoma. PMC

12. Immunoglobulin levels. Many patients have hypergammaglobulinemia, a sign of immune activation. htct.com.br

13. Autoantibody panels. Direct antiglobulin tests, antiplatelet antibodies, and sometimes ANA if lupus-like features are in the differential. BioMed Central

14. Flow cytometry for lymphocyte subsets. Documents lymphoproliferation. Double-negative T cells (αβ-DNTs) may be normal or only mildly raised (unlike classic ALPS). BioMed Central

15. Apoptosis testing (FAS pathway). Normal FAS-mediated apoptosis with clinical ALPS features points away from classic ALPS and toward ALPS-4/RALD. PMC

16. Phospho-ERK (pERK) readouts in lymphocytes (research/advanced). Demonstrates RAS–MAPK pathway activation that supports survival signaling. PMC

17. **Targeted NRAS/KRAS testing on blood (NGS). Confirms a somatic gain-of-function variant, the linchpin of diagnosis. NCBI

18. Broad ALPS/ALPS-like gene panel. If initial testing is negative or the picture is atypical, panels covering FAS, FASLG, CASP10 and many ALPS-like genes (e.g., CTLA4, LRBA, PI3K pathway, STK4) help with the differential. Mayo Clinic Laboratories

D) Electrodiagnostic tests

19. Nerve conduction studies / EMG (only if indicated). Not routine for ALPS-4. Considered only if there is suspected neuropathy from severe autoimmune activity or treatment toxicity; otherwise not part of standard diagnosis. NCBI

20. Electrocardiogram (EKG) for systemic monitoring as needed. Again, not diagnostic for ALPS-4; used pragmatically if anemia is severe or there are medication concerns. These are supportive, not core tests. NCBI

E) Imaging

21. Ultrasound of abdomen. Safely measures spleen and liver size and tracks change over time without radiation. PMC

22. Ultrasound of peripheral lymph nodes. Helps distinguish benign-appearing nodes from worrisome patterns without invasive procedures. PMC

23. CT scan (selected cases). Used when deep nodes or organs need evaluation, or complications are suspected; not routine in stable children. PMC

24. Bone marrow examination (if diagnosis unclear). Helps rule out leukemia/lymphoma and assess marrow during severe cytopenias; often normal or shows autoimmune changes rather than cancer. PMC

Non-pharmacological treatments (therapies and others)

Each item includes a short description (≈150 words), purpose, and mechanism in simple English. These are supportive measures used alongside medical care; they do not replace needed medicines.

1. Education and safety plan
   Description: Learn the disease name (RALD/ALPS-4), the symptoms, and the warning signs of severe anemia, bleeding, or infection. Keep a written plan that lists your diagnoses, usual medicines, and what to do in emergencies. Share it with family and your local clinic. Purpose: Early recognition saves time and reduces risk. Mechanism: In rare disorders, delays happen because people do not recognize urgent signs. A safety plan reduces delays and improves communication. Guidance derived from general ALPS care pathways and rare disease management principles. Medscape

2. Vaccination review (non-live as appropriate)
   Description: Check that routine non-live vaccines (like influenza and pneumococcal) are up to date; avoid live vaccines when you are on strong immunosuppression unless your specialist approves. Purpose: Reduce serious infections during and after treatment. Mechanism: Vaccines train the immune system to prevent specific infections. This is important when medicines may lower immunity, and because splenic enlargement or prior splenectomy (discouraged) can alter infection risk. Medscape+1

3. Infection-prevention habits
   Description: Hand hygiene, prompt fever reporting, dental care, food safety, and avoiding sick contacts when counts are low. Purpose: Lower the chance of bacterial and viral illnesses that can worsen cytopenias. Mechanism: Simple measures reduce exposure load; early assessment allows faster antibiotics when needed. Medscape

4. Nutrition counseling
   Description: Work with a dietitian to meet energy needs, maintain healthy weight, and ensure protein, iron, B12, folate, calcium, and vitamin D are adequate. Avoid raw or high-risk foods if neutropenic. Purpose: Support marrow recovery and reduce infection risk. Mechanism: Balanced nutrients support red cell and immune cell production; safe-food practices reduce pathogen exposure. Medscape

5. Exercise with limits
   Description: Gentle aerobic and strength exercise adapted to the child or adult’s stamina. Avoid contact sports when spleen is enlarged or platelets are low. Purpose: Maintain muscle and bone strength; lower fatigue. Mechanism: Regular light activity improves fitness and mood while minimizing trauma risk from splenomegaly or thrombocytopenia. Medscape

6. Psychological support
   Description: Counseling for stress, anxiety, and school or work adjustments. Peer groups for rare disease families. Purpose: Improve coping and adherence to care. Mechanism: Structured support reduces distress and improves health behaviors and quality of life. Medscape

7. School and workplace accommodations
   Description: Flexible attendance, extra time for assignments after hospital visits, and infection-control measures in classrooms or offices. Purpose: Keep education and employment on track. Mechanism: Practical adjustments reduce stress and exposure without isolating the person. Medscape

8. Sun-exposure and skin care
   Description: Use sunscreen and protective clothing; monitor for rashes or bruising. Purpose: Reduce skin infections and bleeding stigma; protect when platelets are low. Mechanism: Skin care preserves barrier function; sun safety is general good practice for immunosuppressed patients. Medscape

9. Dental hygiene program
   Description: Soft brush, floss, and alcohol-free mouthwash; dental checks timed when platelets are safe. Purpose: Prevent gum bleeding and infections. Mechanism: Lower oral bacterial load and gingival trauma in thrombocytopenia or neutropenia. Medscape

10. Fever plan
    Description: Thermometer at home; clear rule to call or go to the ER for fever ≥38.0°C, especially if neutropenic or on immunosuppressants. Purpose: Rapid evaluation of possible serious bacterial infection. Mechanism: Early antibiotics reduce complications. Medscape

11. Medication adherence coaching
    Description: Pill boxes, reminders, and regular trough-level checks for drugs like sirolimus if used. Purpose: Keep treatment effective and safe. Mechanism: Consistent dosing maintains therapeutic levels and prevents relapses. ASH Publications

12. Bleeding precautions
    Description: Avoid aspirin/NSAIDs when platelets are low; use soft toothbrush; avoid high-impact activities. Purpose: Reduce bleeding risk during ITP flares. Mechanism: Fewer platelet-function inhibitors and less trauma means fewer bleeds. Medscape

13. Transfusion planning
    Description: If you need blood, use irradiated, CMV-safe products per specialist guidance. Purpose: Lower transfusion-related risks. Mechanism: Special processing reduces specific complications in immunodysregulation. Medscape

14. Avoid unnecessary splenectomy
    Description: Discuss evidence showing splenectomy often fails to give lasting benefit and increases sepsis risk in ALPS-like disease. Purpose: Choose safer long-term options first. Mechanism: The spleen is important for defense against encapsulated bacteria; removal raises lifelong infection risk. Frontiers+2PMC+2

15. Family genetic counseling
    Description: Explain that most RALD cases are somatic (not inherited), but counseling helps families interpret results and sibling risks. Purpose: Informed choices and screening. Mechanism: Understanding mutation type (somatic vs germline) guides testing and expectations. PMC

16. Regular specialist follow-up
    Description: Planned visits with immunology/hematology for labs and spleen/lymph node checks. Purpose: Catch relapses early and adjust therapy. Mechanism: Monitoring tracks cytopenias, immunoglobulins, and medicine levels. Medscape

17. Surgery-safety planning
    Description: If any procedure is needed, coordinate with hematology for platelet support and infection prophylaxis. Purpose: Reduce bleeding and infection during procedures. Mechanism: Pre-op optimization lowers peri-operative complications. Medscape

18. Bone health program
    Description: Calcium/vitamin D intake, weight-bearing exercise, and steroid-sparing strategies to protect bones if steroids are used. Purpose: Prevent osteoporosis. Mechanism: Supports bone remodeling and reduces steroid harm. Medscape

19. Sleep and fatigue management
    Description: Sleep schedule, light activity pacing, and screen-time limits at night. Purpose: Reduce fatigue common in chronic immune disease. Mechanism: Better sleep improves daytime energy and immune resilience. Medscape

20. Care coordination and registries
    Description: Enroll in rare-disease registries or centers with ALPS/RALD experience. Purpose: Access to expertise and up-to-date protocols. Mechanism: Specialized teams use evidence-based care and collect outcomes that guide future treatment. ASH Publications

---

Drug treatments

Doses are typical ranges for adults or pediatric weight-based where noted; individual plans must be set by your specialist. Evidence is drawn from ALPS/RALD literature; strong themes include steroid-sparing therapy with sirolimus or mycophenolate, cautious use of rituximab, and avoiding splenectomy where possible. Medscape+3PMC+3ASH Publications+3

1. Prednisone / prednisolone
   Class: Glucocorticoid. Dose/time: Commonly 1–2 mg/kg/day short-term for autoimmune cytopenias; taper as soon as possible. Purpose: Rapid control of hemolysis or severe thrombocytopenia. Mechanism: Broad anti-inflammatory and lymphocyte-suppressing effects that reduce autoantibody production and splenic destruction of blood cells. Side effects: Hyperglycemia, mood changes, hypertension, infection risk, weight gain, bone loss, cataracts. Steroids work fast but are not a good long-term solution due to toxicity; steroid-sparing agents are preferred for chronic disease. Medscape+1

2. Intravenous immunoglobulin (IVIG)
   Class: Pooled IgG. Dose/time: 1–2 g/kg given over 1–2 days for ITP or AIHA flares. Purpose: Short-term rise in platelets or control hemolysis. Mechanism: Competes for Fc receptors and modulates immune networks to reduce autoantibody-mediated destruction. Side effects: Headache, aseptic meningitis, thrombosis risk, hemolysis (rare), renal strain. Often used as a bridge while steroid-sparing therapy is started. Medscape

3. Sirolimus (rapamycin)
   Class: mTOR inhibitor. Dose/time: Oral daily; titrate to trough ~5–15 ng/mL (center-specific). Purpose: Preferred steroid-sparing agent for chronic lymphoproliferation and cytopenias in ALPS-like disease. Mechanism: Blocks mTOR signaling, reducing survival and expansion of abnormal lymphocytes; has shown high response rates in ALPS. Side effects: Mouth sores, high lipids, edema, cytopenias, infection risk; requires drug-level monitoring and interaction checks. ASH Publications+1

4. Mycophenolate mofetil (MMF)
   Class: Antimetabolite immunosuppressant. Dose/time: Often ~600 mg/m² twice daily in children; typical adult 1–1.5 g twice daily. Purpose: Steroid-sparing control of autoimmune cytopenias. Mechanism: Inhibits inosine monophosphate dehydrogenase, limiting lymphocyte proliferation and autoantibody formation. Side effects: GI upset, leukopenia, infection risk, teratogenicity—use contraception if relevant. PMC+1

5. Rituximab
   Class: Anti-CD20 monoclonal antibody. Dose/time: 375 mg/m² IV weekly ×4 (typical for ITP/AIHA). Purpose: Rescue therapy for refractory autoimmune cytopenias when other options fail. Mechanism: Depletes B cells to reduce autoantibody production. Side effects: Infusion reactions, prolonged hypogammaglobulinemia with infection risk, reactivation of hepatitis B; in ALPS this drug is generally avoided unless necessary because of long-term risks and limited durability. PMC+1

6. Cyclosporine (CSA)
   Class: Calcineurin inhibitor. Dose/time: ~3–5 mg/kg/day in divided doses; monitor troughs. Purpose: Second-line to control refractory autoimmunity. Mechanism: Blocks T-cell activation by inhibiting IL-2 transcription. Side effects: Hypertension, nephrotoxicity, tremor, gingival hyperplasia, infections; drug interactions common. Medscape

7. Tacrolimus
   Class: Calcineurin inhibitor. Dose/time: Oral twice daily with trough monitoring. Purpose: Alternative to cyclosporine for refractory cases. Mechanism: Similar T-cell activation block via calcineurin inhibition. Side effects: Nephrotoxicity, neurotoxicity, diabetes risk, infections. Medscape

8. Azathioprine
   Class: Purine analog immunosuppressant. Dose/time: ~1–2 mg/kg/day; check TPMT/NUDT15 activity before use. Purpose: Steroid-sparing for chronic autoimmunity. Mechanism: Impairs purine synthesis and lymphocyte proliferation. Side effects: Myelosuppression, hepatotoxicity, infections, pancreatitis (rare). Medscape

9. Cyclophosphamide (short course)
   Class: Alkylating agent. Dose/time: Intermittent IV or oral short courses in severe refractory autoimmunity under specialist care. Purpose: Rescue when others fail. Mechanism: Broad cytotoxic effect on proliferating immune cells. Side effects: Myelosuppression, hemorrhagic cystitis, infertility risk, infections; requires careful monitoring. Medscape

10. Erythropoiesis-stimulating agents (ESAs)
    Class: Hematopoietic growth factors. Dose/time: Per anemia protocol if appropriate. Purpose: Support anemia management when hemolysis is controlled but marrow is slow. Mechanism: Stimulates red blood cell production. Side effects: Hypertension, thrombosis risk; use selectively. Medscape

11. Granulocyte colony-stimulating factor (G-CSF)
    Class: Hematopoietic growth factor. Dose/time: Intermittent subcutaneous dosing for severe neutropenia crises. Purpose: Reduce infection risk during severe neutropenia. Mechanism: Speeds neutrophil production. Side effects: Bone pain, leukocytosis; avoid over-correction. Medscape

12. Antimicrobial prophylaxis (as indicated)
    Class: Antibiotics/antivirals per risk. Dose/time: For example, trimethoprim-sulfamethoxazole for Pneumocystis risk if on high-dose immunosuppression. Purpose: Prevent opportunistic infections. Mechanism: Directly suppresses likely pathogens. Side effects: Drug-specific; monitor for allergies and marrow suppression with some agents. Medscape

13. Sirolimus + low-dose steroid combo (bridge)
    Class: mTOR inhibitor plus glucocorticoid. Dose/time: Start sirolimus and taper steroids as the sirolimus effect appears. Purpose: Gain quick control, then spare steroids. Mechanism: Steroid gives rapid relief; sirolimus maintains remission by targeting survival signals. Side effects: Combined immunosuppression increases infection risk; monitor carefully. ASH Publications

14. Mycophenolate + IVIG cycles
    Class: Antimetabolite plus immunoglobulin. Dose/time: MMF daily with IVIG for flares. Purpose: Stabilize platelet or red cell counts with fewer steroid days. Mechanism: MMF reduces new autoantibody formation; IVIG blunts acute destruction. Side effects: See above for each agent. PMC

15. Hydroxychloroquine (selected cases)
    Class: Antimalarial immunomodulator. Dose/time: Standard rheumatologic dosing with eye checks. Purpose: Mild immunomodulation in overlap autoimmunity. Mechanism: Interferes with antigen processing and toll-like receptor signaling. Side effects: Retinopathy risk (rare), GI upset, skin changes. Use selectively and with specialist oversight. Medscape

16. Ruxolitinib (selected research/compassionate use)
    Class: JAK1/2 inhibitor. Dose/time: Off-label; specialist centers may consider in certain immune dysregulation states. Purpose: Modulate cytokine signaling in refractory inflammation. Mechanism: JAK-STAT pathway inhibition reduces inflammatory cytokines; evidence in RALD is limited and evolving. Side effects: Cytopenias, infections, lipid changes. ASH Publications

17. Alemtuzumab (rare, last-line)
    Class: Anti-CD52 monoclonal antibody. Dose/time: Specialist, last-line rescue. Purpose: Profound lymphocyte depletion for life-threatening refractory autoimmunity. Mechanism: Depletes T and B cells. Side effects: Severe infections, reactivation risk; requires intensive prophylaxis and monitoring. Medscape

18. Thrombopoietin receptor agonists (eltrombopag/romiplostim) for refractory ITP
    Class: TPO-R agonists. Dose/time: Per ITP labeling. Purpose: Raise platelets when immune destruction persists. Mechanism: Stimulate platelet production in bone marrow. Side effects: Thrombosis risk, liver tests changes (eltrombopag), marrow reticulin increase (usually reversible). Medscape

19. Plasmapheresis (temporary adjunct)
    Class: Apheresis procedure (not a drug, but adjunctive therapy). Dose/time: Short series for fulminant hemolysis while other agents start working. Purpose: Rapid removal of pathogenic antibodies. Mechanism: Physically clears plasma autoantibodies. Side effects: Line complications, electrolyte shifts. Medscape

20. Hematopoietic stem cell transplantation (HSCT) pre-conditioning meds
    Class: Conditioning regimens vary (e.g., fludarabine-based). Dose/time: Specialist protocols. Purpose: Curative intent in extremely severe, refractory cases. Mechanism: Replace the immune system with donor cells lacking the pathologic signaling. Side effects: Intensive—graft-versus-host disease, infections, organ toxicity; reserved for select patients. Medscape

---

Dietary molecular supplements

Always discuss supplements with your team to avoid drug interactions (e.g., sirolimus and CYP3A4 interactions). Evidence in RALD/ALPS is supportive/indirect.

1. Vitamin D3
   Dose: Often 600–1000 IU/day (adjust to blood levels). Function/mechanism: Supports bone health (especially if on steroids) and may modulate immune balance. Medscape

2. Calcium
   Dose: Dietary intake to meet age goals; supplement if low. Function/mechanism: Bone protection during steroid exposure. Medscape

3. Folate
   Dose: 400–800 mcg/day (or as directed). Function/mechanism: Supports red-cell production when recovering from hemolysis; avoid masking B12 deficiency. Medscape

4. Vitamin B12
   Dose: Per deficiency status; oral 1,000 mcg/day common if low. Function/mechanism: Red cell and nerve health; corrects macrocytosis due to deficiency. Medscape

5. Iron (if deficient)
   Dose: As prescribed after ferritin/transferrin studies. Function/mechanism: Builds hemoglobin after hemolysis or blood loss; avoid unnecessary iron if ferritin is high. Medscape

6. Omega-3 fatty acids (fish oil)
   Dose: Typical 1–2 g/day EPA/DHA combined, if no bleeding risk. Function/mechanism: Anti-inflammatory lipid mediators; may improve general inflammatory tone. Medscape

7. Zinc (if low)
   Dose: Replacement to correct deficiency only. Function/mechanism: Supports innate and adaptive immunity; excessive dosing can suppress copper. Medscape

8. Probiotics (with caution)
   Dose: Food-based (yogurt/fermented foods) preferred; avoid live probiotics during profound immunosuppression unless cleared by specialist. Function/mechanism: Gut-immune crosstalk; may support GI health. Medscape

9. Protein-rich oral nutrition supplements (if underweight)
   Dose: As dietitian recommends. Function/mechanism: Provides building blocks for blood cell production and tissue repair. Medscape

10. Multivitamin (age-appropriate)
    Dose: One daily. Function/mechanism: Backstop for small gaps in intake; not a therapy for RALD itself. Medscape

---

Drugs aimed at “immunity booster / regenerative / stem-cell

1. IVIG (immunomodulator/“immune support”)
   Dose: 1–2 g/kg over 1–2 days for flares. Function/mechanism: Provides pooled antibodies that modulate immune activity and can temporarily “balance” overactive immune responses in cytopenias. Medscape

2. Recombinant G-CSF
   Dose: Per protocol for severe neutropenia. Function/mechanism: Stimulates bone marrow to regenerate neutrophils quickly, reducing infection risk during dips. Medscape

3. Erythropoietin (ESA)
   Dose: Per anemia protocol. Function/mechanism: Encourages marrow to make red blood cells after hemolytic crises once hemolysis is controlled. Medscape

4. Thrombopoietin receptor agonists
   Dose: As labeled (eltrombopag/romiplostim). Function/mechanism: Signals megakaryocytes to produce more platelets, supporting counts when immune destruction persists. Medscape

5. HSCT (hematopoietic stem cell transplantation)
   Dose: Procedure with conditioning regimen. Function/mechanism: Replaces the entire immune system with donor cells; only considered for the most severe, refractory disease due to risks. Medscape

6. Sirolimus (immune “resetter” over time)
   Dose: Daily, trough-guided. Function/mechanism: Tamps down abnormal lymphocyte survival signaling (mTOR), helping the immune system regain balance; strong data in ALPS-like disease. ASH Publications

---

Surgeries

1. Excisional lymph node biopsy
   Procedure: Surgical removal of a whole lymph node for pathology. Why: To rule out lymphoma and confirm benign lymphoproliferation when nodes are very large or atypical. Medscape

2. Bone marrow biopsy/aspirate
   Procedure: Needle sampling of marrow cells. Why: To assess blood cell production problems, exclude leukemia, and evaluate unexplained cytopenias. Medscape

3. Central venous port placement (minor surgery)
   Procedure: Implant a small device for reliable IV access. Why: Needed when frequent infusions (IVIG, transfusions) are expected. Medscape

4. Splenectomy (generally avoided)
   Procedure: Surgical removal of the spleen. Why: Historically used for refractory cytopenias, but current guidance advises against routine splenectomy because benefit is often temporary and infection risks are lifelong. Reserved for highly selected cases after exhaustive alternatives. Frontiers+2PMC+2

5. Hematopoietic stem cell transplantation (HSCT)
   Procedure: Conditioning chemo ± antibodies, then infusion of donor stem cells; long inpatient recovery. Why: Potential cure in severe, refractory disease with life-threatening complications that do not respond to medical therapy. Medscape

---

Preventions

1. Keep vaccinations current (non-live if immunosuppressed). 2) Prompt fever reporting plan. 3) Avoid splenectomy unless absolutely necessary. 4) Steroid-sparing long-term strategy (sirolimus/MMF) to limit toxicity. 5) Regular specialist follow-up and labs. 6) Dental and skin care to cut infection risk. 7) Avoid contact sports with big spleen or low platelets. 8) Food safety during neutropenia. 9) Review drug interactions (sirolimus, calcineurin inhibitors). 10) Family counseling and written emergency plan. Medscape+3PMC+3Frontiers+3

---

When to see a doctor

• Fever ≥38.0 °C, chills, or feeling very unwell, especially if neutrophils are low or you are on immunosuppression.

• Bleeding or easy bruising, nosebleeds that do not stop, or new petechiae (tiny red spots).

• Pale or yellow skin, dark urine, fast heartbeat, or shortness of breath suggesting hemolysis.

• Rapid spleen enlargement, severe belly pain, or left shoulder pain (possible splenic issues).

• Severe fatigue, dizziness, fainting, or chest pain.

• New, hard, or rapidly growing lymph nodes, night sweats, or weight loss.
  These signs need urgent assessment to rule out severe cytopenias, infections, or rare malignancy evolution reported in RAS-pathway disorders. PMC+1

---

What to eat” and “what to avoid

• Eat: Balanced meals with lean proteins (eggs, fish, beans) to support blood cell rebuilding. Avoid: Raw/undercooked meats, unpasteurized dairy when neutropenic. Medscape

• Eat: Iron-rich foods (meats, legumes, leafy greens) if iron-deficient per labs. Avoid: Unneeded iron pills if ferritin is high. Medscape

• Eat: Folate and B12 sources (greens, fortified grains, dairy/eggs). Avoid: Assuming diet alone fixes deficiency—check labs. Medscape

• Eat: Fruits/vegetables (washed). Avoid: Raw sprouts and salad bars when neutropenic. Medscape

• Drink: Plenty of water. Avoid: Excess alcohol, which may worsen cytopenias and drug interactions. Medscape

• Choose: Cooked foods in restaurants during low counts. Avoid: Buffet foods with uncertain handling. Medscape

• Consider: Omega-3-rich fish 1–2×/week. Avoid: High-mercury fish if pregnant or as advised. Medscape

• Maintain: Adequate calcium/vitamin D if on steroids. Avoid: High-salt ultra-processed foods that worsen blood pressure on steroids. Medscape

• Include: Yogurt/fermented foods when safe. Avoid: Live probiotic capsules during profound immunosuppression without approval. Medscape

• Plan: Dietitian-guided supplements only as needed. Avoid: Unverified “immune boosters” that can interact with sirolimus or calcineurin inhibitors. Medscape

---

FAQs

1. Is ALPS-4 the same as RALD?
   They are essentially the same clinical entity. What was called ALPS type 4 is now classified as RAS-associated autoimmune leukoproliferative disease (RALD) due to NRAS/KRAS gain-of-function. ASH Publications+1

2. Is RALD inherited?
   Usually no. Most cases are somatic, meaning the mutation happens after birth in some cells only. Family members typically test negative. PMC

3. How is it diagnosed?
   By clinical picture (chronic lymphadenopathy/splenomegaly with autoimmunity), lab features, exclusion of infections/cancer, and genetic testing showing RAS-pathway mutation; classical ALPS tests include Fas-pathway evaluation. NCBI+1

4. How is it different from classical ALPS?
   Classical ALPS is due to FAS/FASLG/CASP10 defects. RALD is due to RAS mutations. They look similar but have different genetic causes and some lab differences. NCBI

5. What is the first treatment for low platelets or anemia?
   Short-course steroids and/or IVIG often control flares, followed by steroid-sparing therapy like sirolimus or MMF for maintenance. PMC+1

6. Is sirolimus really effective?
   Yes. Studies and expert practice show high response rates in ALPS; it is widely used as a steroid-sparing agent in ALPS-like disorders. ASH Publications

7. Should we use rituximab early?
   Usually no. In ALPS, rituximab is reserved for refractory cases because of risk for long-term hypogammaglobulinemia and infections, and because responses may not be durable. PMC+1

8. Is splenectomy a good idea?
   Generally avoid it. It often fails to give lasting remission and increases the risk of life-threatening infections. Frontiers+1

9. Can RALD become cancer?
   RALD is usually chronic and non-malignant, but RAS-pathway disorders can carry some risk for hematologic malignancies; ongoing follow-up is advised. PMC

10. When is HSCT considered?
    Only for severe, refractory disease with life-threatening complications after multiple therapies have failed, because HSCT has significant risks. Medscape

11. Which vaccines are safe?
    Non-live vaccines are important. Live vaccines may be held during significant immunosuppression; ask your specialist. Medscape

12. What daily habits help most?
    Hand hygiene, safe food during neutropenia, dental care, exercise within limits, and sticking to medicines and lab checks. Medscape

13. Does diet cure RALD?
    No. Diet supports health but does not fix the RAS mutation. Use diet to maintain strength and reduce infection risk, alongside medical care. Medscape

14. Can adults have RALD?
    Yes. Presentation can occur in childhood or adulthood. Some adults are diagnosed after years of symptoms. HTCT

15. Where can we read more?
    See GeneReviews, Medscape, Blood journal reviews, and NIH/NCBI/Orphanet rare disease pages linked in citations throughout this guide. Orpha+3NCBI+3Medscape+3

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 29, 2025.

PDF Documents For This Disease Condition References